Objective:To investigate the clinical efficacy of the Shaoyang Zhugu Formula based on the“Shaoyang Governing Bones”theory in treating residual pain after vertebroplasty.Methods:A total of 60 outpatients and inpatien...Objective:To investigate the clinical efficacy of the Shaoyang Zhugu Formula based on the“Shaoyang Governing Bones”theory in treating residual pain after vertebroplasty.Methods:A total of 60 outpatients and inpatients from the Second Orthopedics Ward and Preventive Treatment Center of Chuxiong Prefecture Hospital of Traditional Chinese Medicine between January 2024 and December 2024 were selected and randomly divided into a control group(celecoxib capsules,30 cases)and an observation group(Shaoyang Zhugu Formula+celecoxib capsules,30 cases)using a lottery method.Postoperative pain levels,TCM symptom scores,Japanese Orthopaedic Association(JOA)scores for the lumbar spine,and adverse reactions were compared between the two groups.Results:The observation group showed better pain relief than the control group(P<0.05).The TCM symptom efficacy in the observation group was superior to that of the control group(P<0.05).After two treatment courses,both groups exhibited improved JOA scores,but the observation group demonstrated significantly better postoperative JOA scores(P<0.05).Additionally,the observation group had fewer adverse reactions(P<0.05).Conclusion:The Shaoyang Zhugu Formula,based on the“Shaoyang Governing Bones”theory,effectively alleviates residual pain after vertebroplasty,improves TCM symptoms and lumbar function,and demonstrates high safety.展开更多
目的:从“少阳主枢”理论出发,通过网络药理学和分子对接技术探讨小柴胡汤治疗偏头痛的作用机制。方法:通过(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)数据库获取小柴胡汤有效药物成...目的:从“少阳主枢”理论出发,通过网络药理学和分子对接技术探讨小柴胡汤治疗偏头痛的作用机制。方法:通过(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)数据库获取小柴胡汤有效药物成分及相关靶点;利用在线人类孟德尔遗传数据库(online mendelian inheritance in man,OMIM)、人类基因数据库(the human gene database,GeneCards)获取偏头痛疾病的相关靶点;绘制韦恩图得到小柴胡汤治疗偏头痛的潜在作用靶点;采用STRING数据库、Cytoscape 3.9.1软件构建“药物-成分-疾病-靶点”网络、蛋白-蛋白互作(protein-protein interactions,PPI)网络;使用核心靶基因导入基因功能注释数据库(the database for annotation visualization and integrated discovery,DAVID)对潜在作用靶点进行基因本体论(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)富集分析;运用Autodock软件进行分子对接并用Py-Mol软件进行绘图展示。结果:共获得小柴胡汤有效药物成分214个;小柴胡汤治疗偏头痛的潜在作用靶点148个;使用Cytoscape 3.9.1拓扑分析得到槲皮素、豆甾醇、β-谷甾醇等10个关键成分,PPI网络得到TNF、JUN、AKT1等5个核心靶点;GO功能富集分析得到条目810条,包括生物过程604条,细胞组分73条,分子功能133条;KEGG通路富集分析得到172条信号通路,主要包括脂质与动脉粥样硬化、IL-17、TNF等信号通路;分子对接结果显示关键成分与核心靶点有较好的结合能力。结论:小柴胡汤通过调节IL-17、TNF等信号通路,作用于TNF、JUN、AKT1等核心靶点,以调节大脑炎症反应为核心,对偏头痛发挥治疗作用。展开更多
PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Med...PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment.展开更多
基金Therapeutic Effect of Shaoyang Zhugu Formula on Residual Pain After Vertebroplasty Based on the Theory of Shaoyang Governing Bones(Project No.:XYLH202369)。
摘要Objective:To investigate the clinical efficacy of the Shaoyang Zhugu Formula based on the“Shaoyang Governing Bones”theory in treating residual pain after vertebroplasty.Methods:A total of 60 outpatients and inpatients from the Second Orthopedics Ward and Preventive Treatment Center of Chuxiong Prefecture Hospital of Traditional Chinese Medicine between January 2024 and December 2024 were selected and randomly divided into a control group(celecoxib capsules,30 cases)and an observation group(Shaoyang Zhugu Formula+celecoxib capsules,30 cases)using a lottery method.Postoperative pain levels,TCM symptom scores,Japanese Orthopaedic Association(JOA)scores for the lumbar spine,and adverse reactions were compared between the two groups.Results:The observation group showed better pain relief than the control group(P<0.05).The TCM symptom efficacy in the observation group was superior to that of the control group(P<0.05).After two treatment courses,both groups exhibited improved JOA scores,but the observation group demonstrated significantly better postoperative JOA scores(P<0.05).Additionally,the observation group had fewer adverse reactions(P<0.05).Conclusion:The Shaoyang Zhugu Formula,based on the“Shaoyang Governing Bones”theory,effectively alleviates residual pain after vertebroplasty,improves TCM symptoms and lumbar function,and demonstrates high safety.
摘要目的:从“少阳主枢”理论出发,通过网络药理学和分子对接技术探讨小柴胡汤治疗偏头痛的作用机制。方法:通过(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)数据库获取小柴胡汤有效药物成分及相关靶点;利用在线人类孟德尔遗传数据库(online mendelian inheritance in man,OMIM)、人类基因数据库(the human gene database,GeneCards)获取偏头痛疾病的相关靶点;绘制韦恩图得到小柴胡汤治疗偏头痛的潜在作用靶点;采用STRING数据库、Cytoscape 3.9.1软件构建“药物-成分-疾病-靶点”网络、蛋白-蛋白互作(protein-protein interactions,PPI)网络;使用核心靶基因导入基因功能注释数据库(the database for annotation visualization and integrated discovery,DAVID)对潜在作用靶点进行基因本体论(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)富集分析;运用Autodock软件进行分子对接并用Py-Mol软件进行绘图展示。结果:共获得小柴胡汤有效药物成分214个;小柴胡汤治疗偏头痛的潜在作用靶点148个;使用Cytoscape 3.9.1拓扑分析得到槲皮素、豆甾醇、β-谷甾醇等10个关键成分,PPI网络得到TNF、JUN、AKT1等5个核心靶点;GO功能富集分析得到条目810条,包括生物过程604条,细胞组分73条,分子功能133条;KEGG通路富集分析得到172条信号通路,主要包括脂质与动脉粥样硬化、IL-17、TNF等信号通路;分子对接结果显示关键成分与核心靶点有较好的结合能力。结论:小柴胡汤通过调节IL-17、TNF等信号通路,作用于TNF、JUN、AKT1等核心靶点,以调节大脑炎症反应为核心,对偏头痛发挥治疗作用。
基金Supported by Natural Science Foundation for Youths of Jiangsu Province,China(No.BK20151007)Postgraduate Research&Practice Innovation Program of Jiangsu Province(No.SJLX16_0383)Jiangsu Province Advantage Disciplines Foundation for School of Nursing of Nanjing University of Chinese Medicine(decree No.37 issued by People's Government of Jiangsu Province Office in 2014)
摘要PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment.